GlassScriptPhysician profile
Rekha D Ujla
NPI 1033145883
$2,035.39
in general payments reported to CMS, 2019-2025
21 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $762 · 2022: $394 · 2023: $383 · 2024: $363 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $412.92 | 2022-2024 | Nucala |
| Csl Behring | $322.37 | 2021-2024 | Haegarda |
| Otsuka America Pharmaceutical, INC. | $125.56 | 2024 | |
| Incyte Corporation | $124.99 | 2023 | Opzelura |
| Optinose US, INC. | $122.84 | 2021 | |
| Biocryst US Sales Co., LLC | $120.00 | 2021 | |
| Genzyme Corporation | $112.97 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $112.94 | 2021 | |
| Genentech USA, INC. | $111.11 | 2021 | |
| Verona Pharma, INC. | $110.32 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $98.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $88.35 | 2021 | |
| Alkermes, INC. | $24.64 | 2022 | |
| Dexcom, INC. | $23.62 | 2021 | |
| Abbott Laboratories | $22.98 | 2025 | Freestyle Libre 3 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.44 | 2022 | |
| Indivior INC. | $19.88 | 2023 | Sublocade |
| Phadia US INC. | $16.75 | 2024 | Immunocap |
| Lundbeck LLC | $15.50 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.22 | 2022 | |
| Neurocrine Biosciences, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rekha Ujla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.